Compare · BGM vs NVO
BGM vs NVO
Side-by-side comparison of BGM Group Ltd. (BGM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 3112.3x BGM ($58.8M).
- Over the past year, BGM is down 97.4% and NVO is down 44.1% - NVO leads by 53.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for BGM).
- NVO has more recent analyst coverage (25 ratings vs 0 for BGM).
- Company
- BGM Group Ltd.
- Novo Nordisk A/S
- Price
- $0.35+15.73%
- $42.19+2.89%
- Market cap
- $58.8M
- $183.15B
- 1M return
- +13.56%
- -8.44%
- 1Y return
- -97.41%
- -44.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BGM
- SEC Form 6-K filed by BGM Group Ltd.
- SEC Form 6-K filed by BGM Group Ltd.
- SEC Form 3 filed by new insider Ren Yuehua
- SEC Form 3 filed by new insider Zhai Yaxuan
- SEC Form 3 filed by new insider Xu Waihua
- SEC Form 3 filed by new insider Lou Zefei
- SEC Form 6-K filed by BGM Group Ltd.
- SEC Form 6-K filed by BGM Group Ltd.
- SEC Form 3 filed by new insider Zhang Lin (Henry)
- BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care